Gilead Sciences (GILD) said Monday that a phase 3 breast cancer study met its primary endpoint, showing that Trodelvy plus Keytruda "significantly" improved progression-free survival compared with Keytruda and chemotherapy.
The safety profile of the Trodelvy-Keytruda combination also showed consistency with the know safety profile of each agent, Gilead said.
The company said overall survival is a key secondary endpoint and was not mature during the progression-free survival analysis, but there was an early trend in improved overall survival with the combination.
Merck (MRK) and Gilead entered into a collaboration in 2021 to evaluate the Trodelvy-Keytruda combination compared to Keytruda plus chemotherapy in patients with previously untreated, inoperable locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1, Gilead said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。